Lorvotuzumab

• CAT Number: I042221
• CAS Number: 339306-30-8
• Purity: ≥95%

Lorvotuzumab（Cat No.:I042221）is a monoclonal antibody targeting the cell surface protein CD56, which is overexpressed in various cancer cells, particularly in small cell lung cancer and neuroblastoma. By binding to CD56, Lorvotuzumab can deliver targeted therapy to cancer cells, leading to their destruction. The antibody has been studied for its potential use in cancer immunotherapy, particularly in treating CD56-positive tumors. Clinical trials are investigating Lorvotuzumab’s effectiveness when used alone or in combination with other therapies, with the aim of improving outcomes in patients with aggressive cancers that express CD56.